Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort.
Grinda T, Carton M, Morganti S, Mailliez A, Levy C, Petit T, Bachelot T, Arnedos M, Diéras V, Massard V, Dalenc F, Desmoulins I, Pierga JY, Gonçalves A, Bailleux C, Frenel JS, Bosquet L, Parsons HA, Jacot W, Lin NU